Rheumatology

An Update on Clinical Prospects and Management of Osteoarthritis

The rising prevalence of osteoarthritis (OA) in the general population has necessitated the development of novel treatment options. Over the next few years, several prospective therapies focusing on inflammation, cartilage metabolism, subchondral bone remodelling, cellular senescence and the peripheral nociceptive pathway are predicted to transform the OA therapy landscape. This is a shortened version of the original open access articles.

Modern Medicine – Issue 4 2023

Halt the Pain and Progression of Osteoarthritis

Osteoarthritis (OA) is a chronic degenerative joint disease characterised by pain and progressive functional limitation. Viscosupplementation with intra-articular hyaluronic acid (HA) is a treatment option in knee and hip OA and potentially should apply to all synovial joints in order to reduce pain and improve joint lubrication. Exogenous HA can enhance chondrocyte HA synthesis, prevent the degradation of cartilage, reduce the production of proinflammatory mediators and promote its regeneration.

Modern Medicine – Issue 5 2022

Hyaluronic Acid Pushes Back against Osteoarthritis

Osteoarthritis (OA) is a chronic degenerative joint disease characterised by progressive damage of articular cartilage and underlying bone. It is a common rheumatic disease that affects both genders, especially in older people. Several clinical trials have shown that hyaluronic acid reduces arthritic pain in osteoarthritis of the knee with significant improvements in pain and physical function. It has an excellent tolerability profile with a low incidence of local complications and absence of systemic effects.

Modern Medicine – Issue 5 2021

Hyaluronic Acid Cuts Inflammation in Osteoarthritis

Osteoarthritis (OA) is the most common form of arthritis and one of the leading causes of disability. Over the past decades, there has been an ongoing trend to use intra-articular injections of corticosteroids, analgesics/anti-inflammatory drugs, polymerised collagen, anti-cytokine drugs or hyaluronic acid as alternative modalities to maximise the topical effect and minimise the systemic adverse effects. Each injection has been shown to lower pain in patients in some form, though hyaluronic acid treatments seem to be the safest and to last the longest.

Modern Medicine – Issue 6 2020

Raynaud’s Phenomenon: Time to Take it Seriously – MM1608

The prognosis for people with Raynaud’s phenomenon depends on its severity and whether there is associated underlying medical illness, most commonly an autoimmune disease.

Modern Medicine – August 2016

Managing scleroderma: Challenges in primary care – MM1402

Scleroderma is a complex and challenging connective tissue disease that may affect multiple organ systems.

Modern Medicine – February 2014